Keyphrases
Allogeneic Bone Marrow Transplantation
72%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Autografting
100%
Cell Tolerance
9%
Complete Remission
9%
Days in Hospital
9%
Engraftment
9%
Granulocyte Colony-stimulating Factor (G-CSF)
9%
High Dose
18%
Induction Treatment
9%
Interferon-α (IFN-α)
18%
Marrow
100%
Median Overall Survival
9%
Melphalan
9%
Multiple Myeloma
100%
Neutrophil Recovery
9%
Overall Survival
9%
Peripheral Blood Stem Cell Transplantation
100%
Platelet Recovery
9%
Previously Untreated
100%
Prognostic Factors
9%
Progression-free Survival
18%
Sequential Study
9%
Short Stay
9%
Stem Cells
100%
Survival Outcomes
9%
Survival Probability
9%
Transplant Patients
100%
Untreated Patients
9%
Pharmacology, Toxicology and Pharmaceutical Science
Arsphenamine
100%
Granulocyte Colony Stimulating Factor
50%
Interferon
100%
Melphalan
50%
Multiple Myeloma
100%
Overall Survival
100%
Progression Free Survival
100%
Remission
50%
Immunology and Microbiology
Arm
8%
Bone Marrow Transplantation
66%
Drug Megadose
16%
Engraftment
8%
Granulocyte Colony-Stimulating Factor
8%
Interferon Type I
16%
Multiple Myeloma
100%
Neutrophil
8%
Overall Survival
16%
Peripheral Blood Stem Cell
91%
Platelet
8%
Progression Free Survival
16%
Stem Cell
100%
Stem Cell Transplant
100%
Nursing and Health Professions
Arsphenamine
16%
Bone Marrow Transplantation
66%
Drug Megadose
16%
Engraftment
8%
Granulocyte Colony Stimulating Factor
8%
Interferon
16%
Melphalan
8%
Multiple Myeloma
100%
Overall Survival
16%
Progression Free Survival
16%
Remission
8%
Transplantation
100%
Neuroscience
Arsphenamine
14%
Granulocyte Colony-Stimulating Factor
7%
Interferon
14%
Melphalan
7%
Platelet
7%
Stem Cell
100%